Portal de Periódicos da CAPES

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

2018; National Comprehensive Cancer; Volume: 16; Issue: 11 Linguagem: Inglês

10.6004/jnccn.2018.0084

1540-1413

Michael B. Streiff, Bjorn Holmstrom, Dana E. Angelini, Aneel A. Ashrani, Paula Bockenstedt, C Chesney, John Fanikos, Randolph B. Fenninger, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Paul C. Hendrie, Alfred Ian Lee, Jason T. Lee, Janelle Mann, Brandon McMahon, Michael Millenson, Colleen Morton, Thomas L. Ortel, Sadat Ozair, Rita Paschal, Sanford J. Shattil, Tanya Siddiqi, Kristi J. Smock, Gerald A. Soff, Tzu‐Fei Wang, Eliot C. Williams, Anaadriana Zakarija, Lydia J. Hammond, Mary A. Dwyer, Anita M. Engh,

Cancer Treatment and Pharmacology

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.